1. United Kingdom Stocks

  2. •

    Process industries

  3. •

    Chemicals: agricultural
Eden Biosolutions PLC

Eden Biosolutions PLC

LLSE:EDEN
2.45
GBX
0.00
(0.00%)
2.00BMarket Cap
Dec 16Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
0.01
- -
0.01
0.01
0.01
- -
- -
- -
0.01
0.01
- -
Basic EPS, GAAP
-0.02
-0.01
-0.02
-0.01
-0.01
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.02
- -
- -
Free Cash Flow per Basic Share
-0.02
-0.01
-0.01
- -
-0.01
- -
-0.01
-0.01
-0.01
-0.01
- -
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.06
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.02
0.02
Tangible Book Value per Share
- -
- -
- -
- -
0.01
0.02
0.02
0.01
0.02
0.01
0.01
0.02
0.01
0.01
Basic Weighted Avg Shares
107
122
126
156
179
196
207
209
345
380
381
421
533
533
Sales/Revenue/Turnover
- -
- -
- -
1
- -
2
3
2
1
1
2
3
4
- -
Operating Margin (%)
-3,674.94
-1,975.65
-1,748.17
-128.9
-481.27
-71.99
-17.92
-74.37
-163.86
-261.14
-140.49
-58.48
-50.81
- -
Depreciation Expense
1
1
1
1
1
1
- -
1
1
1
1
6
1
- -
Net Income, GAAP
-2
-2
-3
-1
-2
-1
- -
-1
-2
-3
-2
-6
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,186.32
-1,979.37
-2,973.78
-131
-467.17
-34.05
-12.07
-62.71
-165.84
-227.01
-122.44
-203.45
-44.31
- -
Working Capital
- -
- -
- -
- -
1
3
3
1
8
4
2
8
4
3
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
6
6
6
6
7
9
8
7
15
13
11
14
12
11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-36.88
-26.69
-51.1
-19.5
-28.86
-8.37
-3.99
-14.66
-20.41
-20.13
-19.03
-53.59
-15.05
- -

Capital Structure

GBP

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
533
533
533
Market Capitalization
24
21
20

Working Capital

GBP

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
Total Current Assets
9
8
5
Cash, Cash Equivalents & STI
5
4
2
Accounts Receivable, Net
2
2
1
Inventories
1
1
1
Total Current Liabilities
2
4
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.21%
17.27%
-12.61%
Free Cash Flow
80.62%
24.04%
4.32%
Net Income, GAAP
34.73%
44.21%
-70.64%
Sales/Revenue/Turnover
124.44%
24.59%
34.79%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3
2024
- -
- -
4
2025
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.02
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sean Michael Smith
Full Time Employees
23
Sector
Process industries
Industry
Chemicals: agricultural
Address
67C Innovation Drive Abingdon OX United Kingdom OX14 4RQ
IPO Date
May 11, 2012
Website
edenresearch.com
Similar Companies
UPL Limited (NSE:UPL)
Mosaic Company (The) (NYSE:MOS)
CF Industries Holdings, Inc. (NYSE:CF)
PhosAgro (MOEX:PHOR)
Abou Kir Fertilizers & Chemical Industries Co. (EGX:ABUK)
Misr Fertilizers Production Company MOPCO (EGX:MFPC)
Business
Eden Research plc develops and supplies sustainable biopesticide products and natural microencapsulation technologies primarily for the crop protection, animal health, and consumer products industries. Its core product offerings include crop protection solutions for foliar disease and insect control, applications in open fields and greenhouses, soil pest management, post-harvest shelf-life extension, and seed treatment under brand names such as Mevalone and Cedroz. In animal health, Eden provides shampoos, conditioners, skin disease control, odor control, and flea and tick control products. The company's consumer product range includes head-lice treatments, deodorants, odor neutralizers, fragrances, wound care products, and food flavorings. Eden’s proprietary Sustaine® microencapsulation technology offers a plastic-free, biodegradable delivery system that encapsulates plant-derived active molecules, enhancing efficacy and sustainability. Founded in 1995 and headquartered in Abingdon, United Kingdom, Eden operates mainly within the UK and European markets. Recent major developments include strategic partnerships such as the agreement with French animal health specialist Véto-pharma for thymol supply, new regulatory approvals for products like Mevalone in California and Novellus+ in Mexico, biofungicide and bioinsecticide label extensions in European countries, and appointment of distribution partners in Kenya and Austria. The company has also maintained revenue growth guidance with a reported 34% increase in revenue in 2024, driven by a 38% increase in product sales. Eden has held several new product launches and regulatory authorizations across Europe and North America, reinforcing its expansion in sustainable agricultural inputs. Eden Research continuously pursues business expansions through innovation in natural biopesticides and sustainable chemistry applications, with a strong emphasis on environmentally friendly solutions and plastic-free encapsulation technology. Eden is AIM-listed on the London Stock Exchange under the ticker EDEN and remains focused on advancing low-risk, eco-friendly agricultural and health-related products globally.